Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes by unknown
Nasal Administration Of Glutamate Decarboxylase (GAD65) 
Peptides Induces Th2 Responses and Prevents Murine 
Insulin-dependent Diabetes 
By Jide Tian,* Mark A. Atkinsonfl Michael Clare-Salzlerfl 
Alan Herschenfeld,* Thomas Forsthuber,  II PaulV. Lehmann,II 
and Daniel L. Kaufman** 
From the *Department of Molecular and Medical Pharmacology,  *Brain Research and Molecular 
Biology Institute, University of California, Los Angeles, California 90095-1735; ~Department of 
Pathology, University of Florida, Gainesville, Florida 32610; and [I  Department of Pathology, Case 
Western Reserve University, Cleveland, Ohio 44106 
Summary 
We previously demonstrated that a spontaneous Thl response against glutamate decarboxylase 
(GAD65)  arises in NOD  mice at four weeks in age and subsequently T  cell autoimmunity 
spreads both intramolecularly and intermolecularly. Induction of passive tolerance to GAD65, 
through the inactivation of reactive T cells before the onset of autoimmunity, prevented deter- 
minant spreading and the development of insulin-dependent diabetes mellitus (IDDM). Here, 
we examined whether an alternative strategy, designed to induce active tolerance via the en- 
gagement of Th2 immune responses  to GAD65, before the spontaneous onset of autoimmu- 
nity, could inhibit the cascade of Thl responses  that lead to IDDM. We observed that a single 
intranasal administration of GAD65 peptides to 2-3-wk-old NOD mice induced high levels of 
IgGl antibodies to GAD65. GAD65 peptide treated mice displayed greatly reduced IFN~/re- 
sponses and increased IL-5 responses  to GAD65, confirming the diversion of the spontaneous 
GAD65 Thl  response toward a Th2 phenotype. Consistent with the induction of an active 
tolerance mechanism, splenic  CD4 +  (but  not CD8 +)  T  cells from GAD65  peptide-treated 
mice, inhibited the adoptive transfer of IDDM to NOD-scid/scid mice. This active mechanism 
not only inhibited the development of proliferative T  cell responses  to GAD65, it also limited 
the expansion ofautoreactive T cell responses to other [3 cell antigens (i.e., determinant spread- 
ing).  Finally, GAD65  peptide  treatment reduced insulitis  and long-term IDDM  incidence. 
Collectively, these data suggest that the nasal administration of GAD65 peptides induces a Th2 
cell response that inhibits the spontaneous development of autoreactive Thl responses  and the 
progression of ~ cell autoimmunity in NOD mice. 
W 
e  previously  demonstrated  in  non-obese  diabetic 
(NOD) 1 mice that autoreactive Thl  cell responses 
develop spontaneously and gradually spread both intramo- 
lecularly and  intermolecularly,  creating  a  cascade  of re- 
sponses that ultimately destroys the insulin-secreting ~ cells 
and results  in insulin-dependent diabetes mellitus (IDDM) 
(1).  Autoantigen based therapies offer the  opportunity to 
prevent,  or  inhibit,  this  amplificatory  cascade  through 
mechanisms that are minimally invasive. There are two ba- 
sic  autoantigen-based  immunotherapeutic  strategies.  The 
first  strategy, passive  tolerance, aims to inactivate, or pre- 
1Abbreviations used in this paper: GAD, glutamate  decarboxylase;  hsp, heat 
shock protein; IDDM, insuhn-dependent  diabetes mellitus; NOD, non- 
obese diabetic. 
vent the priming of autoreactive T cells by presenting anti- 
gen without appropriate costimulatory signals, or by inter- 
feting with the formation of  MHC/TCR complexes through 
peptide antagonists or monoclonal antibodies (reviewed in 
references 2  and 3).  Therapies based on passive  tolerance 
are  highly specific,  but require detailed knowledge of the 
target  antigens,  the  effector TCR  or  the  peptide/MHC 
complex they recognize. Therefore, passive  tolerance has 
almost exclusively been used to prevent experimentally in- 
duced autoimmune disease, in which the initiating autoan- 
tigen is defined. 
We  demonstrated  the  efficacy of passive  tolerance  to 
prevent spontaneous ~3  cell autoimmunity in NOD  mice 
by identifying GAD65 as the earliest  known T  cell target 
antigen  and  demonstrating that  inactivation of GAD65- 
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before the loss of self-tolerance, prevented the development 
of [3 cell autoimmunity (1).  The  GAD65 treated mice did 
not  have  detectable levels  of GAD65  autoantibodies  and 
their splenic T  cells failed to protect recipients in adoptive 
transfer experiments, consistent with the induction of pas- 
sive tolerance (J. Tian and D.L. Kaufman, unpublished ob- 
servations). 
The  second  immunotherapeutic  strategy  involves  ad- 
ministering autoantigens  in  modes  that  induce  protective 
immune  responses,  creating active forms  of self-tolerance 
(3-8).  This  approach  does  not  require  knowledge  of the 
initial target  antigen  and  its protective  effect may not  be 
confined only to the administered autoantigen, as the acti- 
vated immune responses may downregulate effector T  cells 
through  "bystander"  suppression  (4).  A  recently  favored 
mechanism  for active  tolerance  involves the  induction  of 
Th2 cells that protect a target tissue via the local release of 
cytokines  that  downregulate  Thl  cells  (9-12).  However, 
evidence demonstrating the protective effects of Th2  cells 
in autoimmune disease has been largely confined to experi- 
mentally induced diseases (4).  In the  case of IDDM,  Th2 
cells have in fact been suggested to be both nonprotective 
and nondiabetogenic in adoptive transfer experiments (13). 
We  reasoned  that  if inactivation  of Thl  responses  to 
GAD65 before the onset of autoimmunity prevents  [3 cell 
autoimmunity in NOD  mice, the early priming of a Th2 
response to GAD65 could also interfere with diabetogene- 
sis--either by diverting the pool of GAD65-reactive pre- 
cursor T  cells from  developing toward a  Thl  phenotype, 
or by downregulating  effector T  cells in  the  target  organ 
via bystander suppression.  It is not known  however,  what 
effect  the  induction  of Th2  responses  to  an  autoantigen, 
before  the  spontaneous  development  of pathogenic  Thl 
responses to that autoantigen, would have on determinant 
spreading and  disease progression. Moreover,  it is unclear 
what modes  of antigen administration would induce  Th2 
responses, whereas antigens are easily delivered to mucosal 
surfaces,  this  treatment  has  been  recently reported  to  in- 
duce a variety of T  cell responses (i.e., peripheral deletion, 
anergy, and activation ofCD4 + and CD8 + cells, references 
4,  6,  14-16).  Here,  we show in NOD  mice, that a single 
nasal administration of GAD65 peptides, before the  onset 
of autoimmunity, induces a Th2  cell response that actively 
diverts/downregulates the development ofautoreactive Thl 
responses and inhibits autoimmune disease progression. 
Materials and Methods 
Mice.  NOD  mice  (Taconic Farms Inc.,  Germantown,  NY) 
were bred under SPF conditions. Only female NOD mice were 
used in this study. Insulitis begins at 4 wk and the average age of 
disease onset in females is at 22 wk. Approximately 80% of the fe- 
male mice display IDDM by 30 wk in age. IDDM increases to 
,'-,90% by 40 wk in age and remains stable thereafter. 
Antiget,s.  We previously characterized in NOD mice the de- 
velopment  of T  cell  autoreactivity to  a  panel  of overlapping 
GAD65 peptides that span the molecule (1). We administered a 
mixture of the synthetic peptides that contain the earliest GAD65 
T cell target determinants (peptides 17, 34, 35, and 36, references 
1 and 17), or a control GAD65 peptide that does not contain a T 
cell target determinant (peptide 11 in references 1 and 17). These 
peptides,  as  well  as  the  hsp65  immunodominant  peptide  (18) 
were prepared as previously described (17).  To  avoid confusion 
between the experimental GAD65 peptides (peptides 17, 34, 35, 
36) that contain T cell determinants and the control GAD65 pep- 
tide (peptide 11) which does not,  we refer to peptide 1l  as the 
"control" peptide. Mouse GAD65 (19) and control Escherichia coli 
J3-galactosidase,  used in T  cell proliferation assays, were purified 
as previously described (I). Human GAD65, used in ELISA assays 
for  autoantibodies,  was  provided  by  Synectics  Biotechnology 
(Stockholm,  Sweden).  Bovine insulin B  chain was from  Sigma 
Chemical Co. (St. Louis, MO). Hen egg white lysozyme peptide 
(HELiI_2s), which  contains  a  dominant  determinant,  was  pro- 
vided by Eli Sercarz. 
Treatment.  Female NOD mice at 2-3 wk were given a single 
intranasal dose of a mixture of four GAD65 peptides (peptides 17, 
34, 35, 36, 50/,g of each in 50/*1 PBS). Control NOD mice re- 
ceived a single dose of the control peptide (200/,g in 50 I*l PBS). 
Mice received peptides while under light ether anesthesia using a 
thin drawn-out plastic tube  (inserted 5-10  mm intranasally) at- 
tached to a Hamilton syringe. At 12 wk, some mice were killed 
to characterize splenic T cell responses and insulitis. The remain- 
ing mice were  followed up  to  1 yr to  determine the  effect of 
treatment on long-term IDDM frequency. Urine glucose levels 
were monitored weekly for diabetes by Tes-tape. After observing 
abnormal glucose in the urine, blood glucose levels were moni- 
tored twice weekly. Two consecutive blood glucose levels >13 
Ltmol/L were considered as IDDM onset. 
GAD65 Autoantibody Assays.  GAD65 (10/*g/ml) was bound 
to  96-well plates  (Nunc)  in  0.1  M  NaHCO  3,  pH  8.5,  at  4~ 
overnight.  The  wells were  rinsed with  PBS  and  then  blocked 
with 3% BSA in PBS for 1 h. Mouse sera was added (0.1 nil of a 
1/500  dilution) and incubated 1 h  at 37~  Following washing, 
bound Ig was characterized using altlnity-purified HRP-coupled 
goat anti-mouse IgG+A+M  (H+L)  (Pierce Chem.),  or HRP- 
coupled goat anti-mouse isotype-specific  antibodies for IgG  1, IgGaa, 
lgM (Southern Biotech Associates) and 2,2'-azino-bis(3-ethylbenz- 
thiazoline-6-sulfonic acid)  (Sigma  Chemical Co.).  Sera  from  un- 
treated BALB/c and AKR mice were used as negative controls. 
Cytokine Assays.  Spleen cells were plated at 8 ￿  10  ~ cells/ml 
in 24-well microtiter plates as previously described (1).  GAD65 
or [3-galactosidase were present at 100/.tg/ml. After 48 h, culture 
supernatants were analyzed by lymphokine-specific ELISA. For 
the IFN"/ELISA, mAb R4-6A2 was used as the capturing agent 
and XMG 1.2-biotin (PharMingen, San Diego, CA) was used in 
conjunction with SAV-AP and PNPP for the detection of bound 
lymphokine.  For  IL-5  detection,  mAb  TR.FK5  and  TP,  YK4- 
biotin (PharMingen)  were used. The  concentration of lympho- 
kines was determined by comparison with a standard curve of re- 
combinant murine IFN~/or IL-5 (PharMingen). 
Adoptive Transfer of Diabetes.  Ten million splenic mononuclear 
cells  from  untreated-diabetic mice  were  mixed  with  an  equal 
number of splenic mononuclear cells from (18-20 wk old) exper- 
imental or control peptide treated mice, and the mixture injected 
i.v. into  10-wk-old NOD-scid/scid mice (20).  A positive control 
group received 1 ￿  107 splenic mononuclear cells obtained from 
only untreated diabetic mice. 
To  examine the T  cell subset that conferred protection from 
the adoptive transfer of disease,  CD4 + and CD8 + splenic T  cell 
populations were  isolated from  5-wk-old control  and  GAD65 
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CD4 + and  CD8 + enrichment  columns  (R&D Systems,  Minne- 
apolis,  MN).  Three-color FACS  |  analysis  using  PE-anti-CD3, 
Cy-chrome-anti-CD4 +,  and  FITC-anti-CD8 +  antibodies  (Phar- 
Mingen)  showed  that  the  negatively selected  CD4 +  subset  con- 
tained less than 1% CD8 + T  cells, and that the CD8 § subset con- 
tained less than 3% CD4 + T  cells.  5  ￿  106 purified T  cell subsets 
from control or GAD65  peptide  treated  mice were mixed with 
107 splenic mononuclear cells from diabetic NOD  mice and in- 
jected i.v. into NOD-scid/scid mice. 
T Cell Proliferation Assays.  At  12  wk  of age  the  mice  were 
killed and their spleen cells were tested directly in vitro for prolif- 
erative responses to GAD65, heat shock protein (hsp65), 13-galac- 
tosidase and the insulin B chain, as previously described (1). 
Histopathology.  At 12  wk of age, pancreata  from control and 
experimental NOD mice (at least five from each group) were ex- 
amined  for insulitis  as  described  previously (1).  The  severity of 
mononuclear  cell infiltration was defined histologically (0  =  no 
lymphocytic infiltration; 1 =  <25%; 2  =  25-50%; 3  =  50--75%; 
4  =  >75%, reference 21). 
Results 
Nasal  Administration  of  GAD65  Determinants  Induces 
GAD65-specific  Autoantibodies  of the IgG  1 Isotype.  Experi- 
mental and control NOD  mice were given a single intrana- 
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Figure  1.  The nasal administration  of GAD65  determinants  induces 
GAD65-specific  autoantibodies  of the IgG  1 isotype.  Female NOD mice 
at 2-3  wk were given a single intranasal dose  of a control peptide,  or 
GAD65 peptides that contain  early T  cell target determinants.  At 12 wk, 
sera from control (&) and GAD65 peptide (O) treated  mice were tested 
for anti-GAD65 antibodies.  The isotype  of the GAD65 antibodies  was 
characterized  using an ELISA assay and isotype-specific antibodies  as de- 
scribed in Materials and Methods.  Unmanipulated NOD mice and con- 
trol peptide-treated mice had low levels of GAD65 autoantibodies,  that 
were only slightly greater than the background  levels we observed in sera 
from BALB/c and ~  mice (data not shown). There was a linear rela- 
tionship between the OD and the titer of the antibody  (data not shown). 
The data are represented  as the mean absorbance values of samples from 
individual mice. The background  OD ranged from 0.05-0.07 in two sep- 
arate experiments. 
sal  dose  of peptides  at  2-3  wk  and  humoral  responses  to 
GAD65  were  tested  at  12  wk,  We  observed  that  NOD 
mice  treated  with  the  control  peptide  had  low  levels  of 
GAD65  autoantibodies  (Fig.  1), similar to that  observed in 
unmanipulated  age-matched  NOD  mice, and  only slightly 
greater  than  that  found  in  BALB/c  and  AKR  mice  (data 
not shown).  However, high levels of GAD65  autoantibod- 
ies were  observed  in  most  of the  GAD65  peptide-treated 
NOD  mice,  indicating  that  the  treatment  triggered  a  T 
cell-dependent  anti-GAD65  B  cell  response.  To  identify 
the type of T  cell that provided help for GAD65  autoanti- 
body production,  we characterized the isotype  of the anti- 
GAD65  immunoglobins.  The  GAD65  autoantibodies  in 
the GAD65  peptide-treated  group were almost exclusively 
of the  IgGl  subclass  (Fig.  1),  which  is  indicative  of Th2 
help  (22,  23).  In  contrast,  IgGaa  GAD65  autoantibodies, 
which  require  Thl  help,  were  at  very low levels in  both 
the  experimental  and  control  groups.  These  data  suggest 
that  nasal  administration  of  GAD65  peptides  activates  a 
GAD65-specific Th2 response. 
T  Cells  from  GAD65 Peptide Treated Mice Display Decreased 
IFN  y  and Increased IL-5 Production in Response to  GAD65. 
We  previously  demonstrated  that  unmanipulated  NOD 
mice at 12 wk have a clonally expanded,  CD4 + L-selectin-, 
IFN~/secreting population of GAD65-specific T  cells, (i.e., 
a  Thl  response  to  GAD65,  reference  1).  Consistent  with 
our previous findings, we observed that T  cells from 12 wk 
old control peptide-treated  NOD  mice secreted high levels 
of IFN'y in response  to  GAD65  challenge in vitro (Fig. 2). 
In  contrast,  T  cells  from  GAD65  peptide-treated  NOD 
mice  displayed  greatly  reduced  IFN~/  responses.  Further- 
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Figure 2.  T cells from GAD65 peptide-treated  mice display decreased 
IFN~/ and increased  IL-5  production in response to GAD65.  Splenic T 
cells from 12-wk-old NOD mice that had received a single nasal adminis- 
tration  at 2-3 wk of experimental  (open bar) or control GAD65 peptides 
(black bar) were tested for their pattern  of cytokine responses to GAD65. 
The IFN3~ responses in the control group were similar to that  found in 
the unmanipulated  NOD mice of our previous study (1). IFN~ or IL-5 
were not detected in cultures  with control 13-galactosidase or medium 
alone (data not shown).  Values shown are mean -+ SEM of triplicate as- 
says in two separate experiments. 
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Figure  3.  Adoptive  cotransfer 
of CD4  +  splenic  T  cells from 
GAD65  pepdde-treated  mice 
protects recipient NOD-scid/scid 
mice from IDDM. (a) At 18-20 
wk,  splenic  mononuclear  cells 
from  mice  treated  with  control 
(A)  or  GAD65  (O)  peptides 
were  cotransferred with T  cells 
from  diabetic  NOD  mice  to 
NOD-scid/sdd mice.  A  positive 
control group received cells only 
from  untreated  diabetic  NOD 
mice (O) (n =  10 for all groups). 
(b) Unfractionated splenic T cells 
(A),  CD4  + (I) and CD8  + (V) 
T  cells from  control  peptide- 
treated  mice,  or  unfractionated 
splenic T  cells ((3), CD4 + ([]) 
and  CD8  +  (A)  T  cells from 
GAD65  peptide-treated  mice, 
were  mixed with  mononuclear 
cells  from  unmanipulated  dia- 
betic  NOD  mice  and  cotrans- 
ferred into NOD-scid/scid mice. 
Positive  control,  unfractionated 
T cells from only untreated  dia- 
betic mice (<)). (n =  8-10 for all 
groups). 
more, while IL-5 secretion was almost undetectable in the 
control  group,  clear  IL-5  responses  were  detectable  in 
some mice of the experimental group, confirming the acti- 
vation of Th2 responses. 
Adoptive  Cotransfer of Splenic T  Cells from  GAD65  Pep- 
tide-treated Mice Protects Recipient NOD-scid/scid  Mice from 
IDDM.  We next examined whether T  cells from GAD65 
peptide-treated  NOD  mice  could  actively  inhibit  the 
adoptive transfer of diabetes. Splenic mononuclear cells from 
mice treated with GAD65 or control peptides were cotrans- 
ferred with T  cells from diabetic NOD  mice to NOD-scid/ 
scid mice. All of the positive control mice that received cells 
from unmanipulated diabetic  NOD  mice, and 90% of the 
mice that received a  mixture of cells from unmanipnlated 
diabetic  and  control peptide-treated  NOD  mice,  became 
diabetic  within 5  wk  after  transfer  (Fig.  3  a).  In contrast, 
only 20% (n =  10) of the NOD-scid/scid mice that received 
a mixture of cells from GAD65 determinant treated mice and 
unmanipulated diabetic mice developed IDDM  (P <0.01). 
Those recipients that did develop IDDM  showed a delayed 
onset of disease relative to the control groups. 
To  examine the  T  cell subset that  inhibited disease de- 
velopment,  splenic  CD4 +  and  CD8 +  T  cell  populations 
were  isolated from the spleens of control or GAD65 pep- 
tide-treated mice and cotransferred with mononuclear cells 
from  diabetic NOD  mice into NOD-sdd/sdd  mice.  Mice 
that  received  CD4 +  or  CD8 +  T  cells from  control pep- 
tide-treated mice progressed to IDDM within 4 wk (Fig. 3 
b). In contrast, the CD4 +, but not the CD8 +, T  cell popu- 
lation of the  GAD65 peptide-treated  mice conferred pro- 
tection from the adoptive transfer of disease, at a level sim- 
ilar to that of unfractionated T  cells from these mice. These 
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Figure 4.  The nasal administration of GAD65 peptides inhibits deter- 
minant spreading ofT cell autoimmunity. Splenic T cells from 12-wk-old 
control (A) or GAD65 peptide-treated  ((3) mice were tested for prolifer- 
ative responses to GAD65, the immunodominant  hsp65 peptide and the 
insulin  B chain. Background for medium alone ranged from 1,200-2,500 
cpm.  Positive control Con A (1  Ixg/ml)-stimulated  T  cell proliferation 
ranged from 38,000-43,000  cpm. The dashed line indicates the level con- 
sidered to be a significant response (threefold above the mean background 
level). Mice from both groups were tested simultaneously in two separate 
experiments. None of the antigens induced proliferation of splenic T cells 
from BALB/c mice (data not shown). 
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Figure 5.  The nasal administration of GAD65 peptides inhibits IDDM. 
Female NOD mice at 2-3 wk were given a single intranasal dose of con- 
trol (&) or GAD65 peptides (O) and were followed up to 52 wk to deter- 
mine the effect  of treatment on long-term IDDM incidence as described 
in Materials and Methods. (n = 15 for each group). 
data  demonstrate that  the  nasal administration  of GAD65 
peptides can induce potent CD4 + regulatory cells that sup- 
press the adoptive transfer of IDDM. 
The Nasal Administration of GAD65 Peptides Inhibits Spread- 
ing ofT Cell Autoimmunity.  Splenic  T  cells  from  12-wk- 
old  experimental  and  control  mice  were  tested  for  their 
proliferative responses to 13 cell autoantigens.  T  cells  from 
control  mice  displayed  strong  proliferative  responses  to 
GAD65 and hsp65  and some of the mice displayed T  cell 
responses  to  insulin  B  chain  (Fig.  4).  The  levels of these 
proliferative responses were similar to those we observed in 
untreated  NOD  mice  (1).  In  contrast,  nearly  all  of the 
NOD mice treated with peptides containing GAD65 target 
determinants  failed  to  display  significant  proliferative  re- 
sponses to GAD65 (Fig. 4). Furthermore, none of the mice 
in the experimental group displayed significant proliferative 
responses to hsp65 or the B chain of  insulin. Thus, the nasal 
administration of GAD65 determinants inhibited the inter- 
molecular spreading of the autoreactive Thl  responses that 
naturally occur in NOD mice. 
The Nasal Administration of Key GAD65 Peptides Reduces 
Insulitis and IDDM Incidence.  Examination  of the pancre- 
ata from 12-wk-old control mice revealed that all islets had 
infiltrating  lymphocytes  at  levels  essentially  identical  to 
those  we  observed in  unmanipulated  NOD  mice  (1).  In 
contrast,  several of the  pancreata  from the  GAD65  pep- 
tide--treated  group  were  virtually  free  of insulitis.  The 
overall insulitis score for pancreata from mice in the exper- 
imental group (0.9  +  0.4) was less than half that ofpancre- 
ata from the control group (1.9  +  0.7). 
We next examined the effect of GAD65 peptide admin- 
istration  on  the long-term frequency of IDDM in  NOD 
mice. 90% of the mice receiving the control peptide were 
diabetic  by 35  wk  (Fig.  5),  matching  the  time  course  of 
IDDM incidence observed in unmanipulated female NOD 
mice. In contrast, 60% of the GAD65 peptide--treated mice 
remained disease free at 52 wk  (P <0.03),  and those that 
did become diabetic  displayed a  delayed onset  of disease. 
Thus,  the  single  nasal administration  of GAD65  determi- 
nants early in life significantly delayed, or prevented, IDDM 
onset. 
Interestingly, high levels of anti-GAD65  IgG  1 autoanti- 
bodies were detected in the sera of all 52-wk-old GAD65 
peptide treated mice that had remained disease free. How- 
ever, GAD65 autoantibody levels greatly dechned just be- 
fore disease onset in the GAD65-treated mice which devel- 
oped IDDM (data not shown). 
Discussion 
The NOD  mouse has been suggested to be deficient in 
Th2  development (24)  and  the  spontaneous  autoimmune 
response  to  13  cell  antigens  in  NOD  mice  appears to  be 
highly Thl  biased (1),  factors which may predispose these 
mice to IDDM susceptibility. We hypothesized that if Th2 
responses  could  be  induced  to  13  cell  autoantigens  at  an 
early age, it might inhibit the development of pathogenic 
Thl  responses  and  autoimmune  disease  progression.  As 
GAD65  is a  key initial  target antigen  in  NOD  mice, we 
examined whether it is possible to administer GAD65 in a 
mode  that  would  induce  GAD65-specific  Th2  responses 
and shift the development ofa Thl biased anti-GAD65 re- 
sponse in NOD mice. 
We  observed that  a  single  intranasal  administration  of 
GAD65 peptides induced high levels of IgG1 anti-GAD65 
antibodies and greatly reduced IFN~/while increasing IL-5 
responses to GAD65, apparently shifting the normal Thl/ 
Th2 balance toward a Th2  response.  Consistent  with the 
induction of an active tolerance mechanism, splenic T  cells 
from GAD65 peptide-treated mice inhibited the adoptive 
transfer of disease to NOD-sdd/scid mice. This protection 
was  conferred  by the  CD4 +,  and  not  the  CD8 +,  T  cell 
subset.  This active mechanism inhibited  the  development 
of proliferative T  cell responses to GAD65 as well as other 
13 cell antigens and reduced insuhtis and long-term IDDM 
incidence. While GAD65 autoantibodies remained high in 
the GAD65 peptide-treated mice that did not develop dis- 
ease,  GAD65  autoantibody  levels  greatly declined  in  the 
GAD65-treated mice which  developed IDDM,  consistent 
with Th2 regulation of IDDM development. Collectively, 
these data suggest that the nasal administration of GAD65 
peptides  interferes with  the  development of the  diabeto- 
genic process through the induction ofa Th2 response (ac- 
tive  tolerance),  rather  than  the  clonal  inactivation  of 
GAD65-reactive cells (passive tolerance). 
The  mechanism  by  which  the  induction  of Th2  re- 
sponses  interferes  with  disease  progression  may  involve 
one, or several, of the following:  (a) the induction of Th2 
responses before the spontaneous priming of Thl responses 
may have driven a limited number of uncommitted, or not 
fully differentiated, Th0 cells toward a Th2 lineage; (b) the 
1565  Tian et al. first generation of Th2 cells  may have migrated to the tar- 
get organ where their local secretion ofcytokines may have 
downregulated  antigen  presentation  in  the  islets  (25,  26), 
thereby  limiting  the  amplificatory  cascade  of  Thl  re- 
sponses;  (c)  alternatively,  the  local release  of cytokines by 
Th2 cells  may have upregulated islet  antigen presentation, 
which in the  absence of appropriate  costimulatory factors, 
caused the  antigen-specific  T  cells  that  engaged these  de- 
terrninants  to be anergized or deleted  (27),  or;  (d)  the up- 
regulation of islet antigen presentation  may have caused T 
cell priming that was Th2 biased due to the IL-4 environ- 
ment  that  was  established  by the  first  wave  of Th2  cells, 
creating an amplificatory cascade of Th2 responses;  (e) The 
GAD-specific  Th2  response  may have  locally downregu- 
lated  Thl  cells  through  the  secretion  of cytokines  such 
as IL-10 and IL-4 (bystander suppression,  references 4,  10, 
11, 22). 
Th2 cells  are generally thought to exert protective func- 
tions in experimental  models of autoimmune disease  (3,  4, 
9,  15)  and  administration  of  IL-4  and  IL-10  are  anti- 
inflammatory (24, 28).  However, two recent reports ques- 
tion whether Th2 cells  exert  anti-inflammatory functions. 
Katz et al.  showed that Th2 cells fail to mitigate  [3 cell de- 
struction when coinjected with Thl  cells in adoptive trans- 
fer experiments  (13).  Our conflicting findings may be due 
to differences in the nature and frequency of the autoanti- 
gen-reactive T  cells used in our experiments.  Katz et al.  si- 
multaneously injected clonal populations of preactivated  13 
cell-specific Thl  and Th2 cells.  Under these  conditions it 
is  likely that  Th2  cell  secreted  cytokines  could  not  exert 
regulatory functions before Thl  cells engaged target deter- 
minants.  We  injected  a  mixed  population  of unactivated 
spleen cells, in which the frequency of GAD65-reactive T 
cells  was  ,--,1 in  104-105 .  Our  protocol  may  not  have 
flooded the target organ with an autoreactive Thl  compo- 
nent,  thus providing an opportunity for Th2 cells  to exert 
protective  functions.  These  experiments  also  targeted  dif- 
ferent 13 cell antigens, whereas our protocol induced GAD65- 
specific Th2 cells,  the T  cell populations used by Katz et al. 
have an unknown specificity. 
Apparently also contradicting the protective Th2 cell hy- 
pothesis,  is the finding that  IDDM is accelerated  in trans- 
genic mice expressing IL-10 in their 13 cells  (29). However, 
IL-10 may have complex functions.  For example,  IL-10 is 
a  growth factor for CTL and facilitates  their priming  (30, 
31).  Since CD8 + cells are involved in the pathogenesis  of 
IDDM in NOD  mice (32,  33),  the IL-10 produced in the 
transgenic  islets  may have promoted an anti-J3  cell CD8 + 
response and accelerated disease progression. It is also possi- 
ble that other cytokines such as IL-4 and IL-13 mediate the 
anti-inflammatory functions of Th2 cells.  Thus,  these two 
reports do not disprove a protective role for Th2 cells.  To 
the contrary, our data substantiate  the contention that Th2 
cells can serve a protective role. 
In conclusion, we have shown that a single nasal admin- 
istration  of peptides  containing T  cell  target  determinants 
can induce antigen-specific  Th2 responses  and inhibit  the 
spontaneous cascade of events that lead to IDDM. Thus the 
inhalation  of autoantigen  peptides  may provide  an  easily 
administered,  minimally  invasive,  immunotherapy  to pre- 
vent spontaneous autoimmune disease. 
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